alpha -(1-PIPERAZINYL)ACETAMIDO ARENECARBOXYLIC ACID DERIVATIVES AS ANTIDIABETIC AGENTS

Abstract: The invention relates to compounds of general formula (I). These compounds are useful in the treatment of diabetes.

Description: α-(l-PIPERAZINYL)ACETAMIDO ARENECARBOXYLIC ACID DERIVATIVES AS ANTIDIABEΗC AGENTS The present invention relates to new α-(1-piperazinyl)acetamido arenecarboxylic acid derivatives which are useful in the treatment of diabetes. The subject of the present invention is thus compounds of general formula (I): in which: Ar is selected from - a mono-, bi- or tricyclic aryl group having from 6 to 14 carbon atoms, - a heteroaromatic group selected from the pyridyl, pyrimidinyl, pyrrolyl, furyl, thienyl, quinolyl, indolyl, benzothienyl, benzofuryl, benzopyranyl, benzothiopyranyl, dibenzofuryl, carbazolyl and benzothiazinyl groups, it being possible for the Ar group to carry 1 to 3 substituents selected from a Cι-C 8 alkyl, (C 3 -C 8 )cycloalkyl(Cι-C 6 )alkyl, d-C 8 alkoxy, (C 3 - C 8 )cycloalkyloxy(C 1 -C 6 )alkyl, (C3-C 8 )cycloalkyl(Cι-C 6 )alkoxy(Cι-C 6 )alkyl, (C 3 - C 8 )cycloalkyloxy, (C 3 -C 8 )cycloalkyl(C 1 C 6 )alkoxy, (Cι-C 6 )alkoxy(C 1 -C 6 )alkyl, C 6 -C 14 aryl, C 6 -d 4 heteroaryl, (C 6 -Ci 4 )heteroaryl(C 1 -C 6 )alkyl, (C 6 -C 14 )aryl(C 1 -C 6 )alkyl, (C 6 -Cι 4 )aryl(Cι-C 6 )alkyl(C 6 -Cι 4 )aryl, (C 6 -C 14 )aryloxy, (C 6 -C 14 )aryloxy(C 1 -C 6 )alkyl, (C 6 -C 14 )aryl(C 1 -C 6 )aikyloxy or (C 6 -C 14 )aryl(Cι-C 6 )alkyloxy(Cι-C 6 )alkyl group, a halogen, a trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, nitro, amino, carboxyl, (Cι-C 6 )alkoxycarbonyl, carbamoyl, (C 1 -C 8 )alkylthio, (C 1 - C 8 )alkylsulphinyl, (C 1 -C 8 )alkylsulphonyl, sulphoamino, (d- SUBSTΠTJTE SHEET (Rule 26) C 8 )alkylsulphonylamιno, sulphamoyl or (Cι-C 8 )alkylcarbonylamιno group or two of these substituents forming a methylenedioxy group, the 4-carboxyphenyl and substituted 4-carboxyphenyl groups being excluded from the definition of Ar, Ri, R 2 and R 3 are selected, independently of one another, from - a hydrogen atom, - a Ci-Cs alkyl or (Cι-C 6 )alkoxy(Cι-C 8 )alkyl group, - a cycloalkyl group containing from 3 to 8 carbon atoms a (C 3 - C 8 )cycloalkyl(Cι-C 6 )alkyl group or a (C 3 -C 8 )cycloalkyloxy(C 1 -C 6 )alkyl or (C 3 - o C 8 )cycloalkyl(Cι-C 6 )alkoxy(Cι-C 6 )alkyl group, - a C 6 -C 1 aryl, C 6 -Cι 4 heteroaryl, (C 6 -Cι 4 )heteroaryl(Cι-C 6 )alkyl (C 6 -d 4 )aryl(d-C 6 )alkyl, (C6-Cι 4 )aryl(Cι-C 6 )alkyl(C 6 -d 4 )aryl, (C 6 -C 14 )aryl(Cι-C 6 )- alkoxy(d-C 6 )alkyl or (C 6 -Cι 4 )aryloxy(d-C 6 )alkyl group, A, B, C and D are =CH- groups, it being possible for one or two of 5 them also to be a nitrogen atom, R 4 , R 5 and R 6 are selected, independently of one another, from - a hydrogen atom, - a Cι-C 8 alkyl, (C 3 -C 8 )cycloalkyl(Cι-C 6 )alkyl, d-C 8 alkoxy, (C 3 - Cs)cycloalkyioxy(d-C 8 )alkyl, (C 3 -C 8 )cycloalkyloxy, (C 3 -C 8 )cycloalkyl(d- o C 6 )alkoxy (C 3 -C 8 )cycloalkyl(Cι-C 6 )alkoxy(d-C 6 )alkyl, (d-C 6 )alkoxy(d-C 6 )alkyl, C 6 -C 14 aryl (C 6 -Cι 4 )aryl(d-C 6 )alkyl (C 6 -C 14 )aryl(d-C 6 )alkyl(C 6 -C 14 )aryl, (C 6 - Cι 4 )aryloxy, (C 6 -Cι )aryloxy(d-C 6 )alkyl, (C 6 -Ci 4 )aryl(d-C 6 )alkoxy or (C 6 - Cι 4 )aryl(Cι-C 6 )alkyloxy(C 1 -C 6 )alkyl group, a halogen or a trifluoromethyl, trifluoromethoxy, cyano, carboxyl, hydroxyl, nitro, ammo, (d-C 6 )alkoxycarbonyl, 25 carbamoyl, (Cι-C 6 )alkylthιo, (d-C 8 )alkylsulphιnyl, (d-C 8 )alkylsulphonyl, sulphoammo, (Cι-C 8 )alkylsulphonylamιno, sulphamoyl or (Ci- C 8 )alkylcarbonylamιno group, it being possible for two of these groups to form a methylenedioxy group or a phenyl ring condensed with the ring to which they are attached "><> it being possible for the various aryl groups to be themselves substituted by 1 to 3 substituents selected from a d-C 8 alkyl or d-C 8 alkoxy group, a halogen or a trifluoromethyl, trifluoromethoxy, hydroxyl, nitro and ammo group, their solvates and their pharmaceutically acceptable salts Mention may be made, as an example of the aryl group, of the phenyl, α-naphthyl, β-naphthyl and fluorenyl groups The Cι-C 8 alkyl groups can be linear or branched Mention may be ^ made, as examples, of the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert- butyl and pentyl groups The Cι-C 8 alkoxy groups can likewise be linear or branched Mention may be made, as examples, of the methoxy ethoxy, propoxy isopropoxy, butoxy and isobutoxy groups 0 The halogens can be selected from fluorine, chlorine, bromine and iodine The heteroaryl groups in the definition of R^ R 2 and R 3 may be defined in particular as defined for the heteroaromatic groups in the definition of Ar The invention also relates to the tautomeric forms and to the enantiomers, diastereoisomers and epimers of the compounds of general formula (I) The compounds of general formula (I) possess a carboxylic acid functional group and can be sa fied, then existing in the form of salts with bases o Examples of salts with bases of the compounds of general formula (I) include the pharmacologically acceptable salts, such as the sodium salts potassium salts, calcium salts and other salts of the same type The compounds of general formula (I) can also be sahfied with amines in order to form pharmaceutically acceptable salts By way of example 2^ the compounds of general formula (I) could be sahfied with glucamine, N- methylglucamine, N,N-dιmethylglucamιne, ethanolamme, morpholine N-methylmorpholine or lysine The compounds of general formula (I) possess basic nitrogen atoms and can be monosalified or disalified with inorganic or organic acids ) Examples of salts with acids of the compounds of general formula (I) include the pharmaceutically acceptable salts, such as, and non-exhaustively, the hydrochlonde, the hydrobromide, the sulphate, the succmate, maleate, fumarate malate or tartrate and the sulphonates, such as the methanesulphonate, the beπzenesulphonate or the toluenesulphonate. The invention also relates to a process for the preparation of the compounds of general formula (I). A preparation process according to the invention comprises the reaction of an aromatic amine of general formula (II): in which A, B, C, D, R^ R 4 , R 5 and R 6 are as defined above and R 7 is a hydrogen atom, a d-C 6 alkyl group or a benzyl group, with a haloacyl halide of general formula (III): in which R 2 and R 3 are as defined above, Hal represents a chlorine or bromine atom, in order to form a compound of general formula (IV): in which A, B, C, D, R,, R 2 , R 3 , R 4 , R 5 , Re, R 7 and Hal are as defined above, and the reaction of the compound of general formula (IV) with a compound of general formula (V): in which Ar is as defined above, in the presence of a basic agent, such as tnethylamine, in order to form the compound of general formula (VI) in which Ar, A, B, C, D, R 1 : R 2 , R 3 , R 4 , R 5 , R 6 and R- are as defined above In the case where R 7 is an alkyl group, the compound of general formula (VI) can be hydrolysed by conventional acidic or basic means in order to give the compound of general formula (I) In the case where R 7 is a benzyl group, the compound of general formula (VI) can be hydrogenolysed in the presence of a catalyst, such as palladium-on-charcoal, in order to give the compound of general formula (I) The compounds of formulae (II) and (V) are known compounds or ^ can be prepared according to known processes Thus, compounds of formula (II) are described in Organic Preparation and Procedures International, 13, 189, 1981 The compounds of formula (V) can be prepared as described by R Ratouis et al (J Med Chem , 8, 104, 1965) or by Prelog et al (Collection 0 Czechoslov Chem Communications, 6, 211 , 1934) By way of example, the compound (VI), in which R 7 is an alkyl group, can by hydrolysed in the presence of a basic agent, such as dilute sodium hydroxide The enantiomers of the compounds of formula (I) can be separated by successive recrystallization of the salt of the acid (I) with an optically active base in solvents such as acetone, ethyl acetate or isopropanol and then displacement from the salt into an optically active acid by an inorganic or organic acid, according to a conventional method The compounds according to the present invention can be used in the treatment of diabetes, in particular of non-insu n-dependent diabetes, because of their hypoglycaemic effect and of their absence of toxicity at the active doses Another subject of the present invention is thus pharmaceutical compositions comprising an effective amount of a compound according to the invention The pharmaceutical compositions according to the invention can be presented in forms intended for parenteral, oral rectal, permucosal or 5 percutaneous administration They will thus be presented in the form of injectable solutions or suspensions, or multi-dose containers, in the form of uncoated or coated tablets, of sugar-coated tablets, of capsules, including hard gelatin capsules, of pills, of cachets, of powders, of suppositories or of rectal capsules, of solutions or of o suspensions, for percutaneous use in a polar solvent or for permucosal use The excipients which are suitable for such administrations are derivatives of cellulose or microcrystalhne cellulose, alkaline-earth metal carbonates, magnesium phosphate, starches, modified starches or lactose for the solid forms Cocoa butter or polyethylene glycol stearates are the preferred excipients for rectal use Water, aqueous solutions, physiological solution or isotonic solutions are the most conveniently used vehicles for parenteral use The dosage can vary within wide limits depending on the o therapeutic indication and the administration route, as well as the age and weight of the patient The following examples illustrate the preparation of the compounds of formula (I) and of the intermediates of formulae (II) and (IV). A - Example of the preparation of a compound of formula (II). Preparation of methyl 2-cvclohexylmethylamino-5-methoxybenzoate 17.6 g of methyl 5-methoxyanthranilate, 11.8 ml of cyclohexanecarboxaldehyde and 2 g of 10% palladium-on-charcoal (50% water) are charged to 200 ml of methanol in a 1 litre hydrogenation apparatus. The apparatus is placed under a hydrogen atmosphere and agitated at room temperature for 3 hours. 300 ml of dichloromethane are added, the palladium-on-charcoal is separated off by filtration and the filtrate obtained is concentrated under vacuum. The oil obtained crystallizes from an ethanol (200 ml) and water (50 ml) mixture to give 25.4 g of a yellow solid which melts at 58-60°C. 5 IR: (KBr) 1683 cm "1 (C=O), 1528 cm "1 (C=O) 1 H NMR: (CDCI 3 , 200 MHz) δ ppm: 1.06-1.64 (11 H, m, cyclohexyl), 2.93 (2H, t, CH 2 ), 3.68 (3H, s, OCH 3 ), 3.78 (3H, s, OCH 3 ), 6.56 (1 H, d, phenyl proton), 6.96 (1 H, dd, phenyl proton), 7.34 (2H, d + s, phenyl proton + NH). The formulae and characteristics of the compounds of formula (II) o have been combined in Table I. TABLE B - Example of the preparation of a compound of formula (IV). Preparation of 4-chloro-2-(chloroacetamido)benzoic acid 25 5 ml of chloroacetyl chloride are added dropwise with stirring to 50 g of 2-amιno-4-chlorobenzoιc acid in 600 ml of dioxane, the reaction mixture being maintained at 20°C Stirring is then maintained for 2 hours at room temperature and then 1200 ml of water are added The desired product precipitates, the mixture is stirred for one hour and then filtered and the solid obtained is washed with water After drying, 60 7 g of 4-chloro-2-(chloroacetamιdo)benzoιc acid are obtained, the melting point of which is 194-196°C IR 1676 cm "1 (C=0) 1 H NMR (dβ-DMSO, 200 MHz) δ ppm 4 30 (2H, s, CH 2 ), 7 1 (1 H d phenyl proton), 7 7 (1 H, d, phenyl proton), 8 5 (1 H, s, phenyl proton), 1 1 75 (1 H s, NH), 13 90 (1 H, broad s, COOH) The formulae and characteristics of the compounds of formula (IV) have been combined in Table II TABLE II TABLE II (continuation) TABLE II continuation C - Example of the preparation of a compound of formula (II) Preparation of 4-chloro-2-(r4-(2-methoxyphenyl)-1 -piperazinvπacetamido) benzoic acid 15 g of 4-chloro-2-(chloroacetamιdo)benzoιc acid are added, with stirring and at room temperature, to 11 6 g of 1 -(2-methoxyphenyl)pιperazιne and 17 ml of tnethylamine in 120 ml of DMF The reaction mixture is kept stirring for 48 hours at room temperature and then 500 ml of water are added Extraction is carried out with 3 * 300 ml of dichloromethane The solvent is evaporated under vacuum and the solid thus obtained is taken up again in 300 ml of a 2N aqueous sodium hydroxide solution The solution is washed with 3 x 200 ml of diethyl ether and the aqueous phase is then acidified with acetic acid A solid crystallizes to give, after filtration, 22 5 g of crude product After recrystallization from dioxane, 21 1 g of 4-chloro-2-{[4-(2-methoxyphenyl)- 1 -pιperazιnyl]acetamιdo}benzoιc acid are obtained in the form of a white solid which melts at 218-220°C IR 1699 cm "1 (C=O), 1673 cm "1 (C=O) 1 H NMR (CF 3 COOD), δ ppm 4 25 (3H, s, OCH 3 ), 4 65 (8H, broad * s, 4 CH 2 ), 4 95 (2H, s, CH 2 ), 7 5 (2H, m, phenyl protons), 7 6 (1 H, d, phenyl proton), 7 90 (2H, m, phenyl protons), 8 50 (1 H, d, phenyl proton), 8 75 (1 H, s, phenyl proton) D - Alternative form of the preparation of a compound of formula (I) 0 Preparation of 2-{r4-(4-fluorophenyl)-1 -piperazinvn- acetamido)-4,5-(methylenedioxy)benzoic acid 1 5 g of 2-(chloroacetamιdo)-4,5-(methylenedιoxy)benzoιc acid are added with stirring and at room temperature, to 1 0 5 g of 1 -(4- fluorophenyl)pιperazιne and 16 2 ml of tnethylamine in 150 ml of DMF ^ The reaction mixture is kept stirring for 48 hours at room temperature 3 5 ml of acetic acid are added and 150 ml of water are slowly added The acid crystallizes and is diluted with 300 ml of water The mixture is stirred for 30 minutes and filtered and the solid obtained is washed with water 0 After recrystallization from a dioxane/DMF mixture, 14 9 g of 2-{[4- (4-fluorophenyl)-1 -pιperazιnyl]acetamιdo}-4,5-(methylenedιoxy)benzoιc acid are obtained, which product melts at 254-256°C IR (KBr) 1654 cm "1 (C=O) 1 H NMR (CF 3 COOD, 200 MHz) δ ppm 4 40 (8H, s, piperazmyl) ^ 4 67 (2H s, CH 2 ), 6 05 (2H, s, O-CH 2 -O), 7 30 (2H, t, phenyl proton), 7 65 (3H m phenyl proton), 7 90 (1 H, s, phenyl proton) The formulae and characteristics of compounds of formula (I) have been combined in Table III TABLE III ">-> Results of the pharmacological studies will be given herembelow Study of the anti-diabetic activity in the NOSTZ rat The anti-diabetic activity of the compounds of formula (I) by the oral route was determined with respect to an experimental model of non-insu n- dependent diabetes induced in the rat by streptozotocm The non-insulm-dependent diabetes model is obtained in the rat by a neonatal (the day of birth) injection of streptozotocm The diabetic rats used are 8 weeks old The animals are kept, from the day of their birth to the day of the experiment, in an animal house at a temperature regulated from 21 to 22°C and subject to a fixed cycle of light (from 7 h to 19 h) and of darkness (from 19 h to 7 h) Their feeding consisted of a maintenance diet, water and food was supplied "ad libitum", except for fasting for 2 hours before the test when the food is withdrawn (post-absorptive state) The rats are treated orally during the day with the test product Two hours after the final administration of the product and 30 minutes after anaesthetizing the animals with sodium pentobarbital (Nembutal ), a 300 μl blood sample is taken from the end of the tail The mam results obtained are combined in Table IV These results show the effectiveness of the compounds of formula (I) in decreasing glycaemia in the diabetic animals These results are expressed as percentage of change in glycaemia at D4 (4 days of treatment) in comparison with DO (before treatment) TABLE IV

Claims: CLAIMS A compound selected from the compounds of the formula (I) ^ in which Ar is selected from - mono-, bi- or tricyc c aryl having from 6 to 14 carbon atoms, - a heteroaromatic group selected from the pyridyl, pyrimidinyl pyrrolyl furyl, thienyl, quinolyl, indolyl, benzothienyl, benzofuryl, beπzopyranyl o benzothiopyranyl, dibenzofuryl, carbazolyl and benzothiazinyl groups, it being possible for the Ar group to carry 1 to 3 substituents selected from d-C 8 alkyl, (C 3 -C 8 )cycloalkyl(C 1 -C 6 )alkyl, Cι-C 8 alkoxy, (C 3 - C 8 )cycloalkyloxy(C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl(C 1 -C 6 )alkoxy(C 1 -Ce)alkyl, (C 3 - C 8 )cycloalkyloxy, (C 3 -C 8 )cycloalkyl(Cι-C 6 )alkoxy, (CrC 6 )alkoxy(Cι-C 6 )alkyl C 6 - ι C 14 aryl, C 6 -Cι 4 heteroaryl, (C 6 -C 14 )heteroaryl(Cι-C 6 )alkyl, (C 6 -Cι 4 )aryl(Cι- C 6 )alkyl (C 6 -C 14 )aryl(C 1 -C 6 )alkyl(C 6 -Cι 4 )aryl, (C 6 -Cι 4 )aryloxy, (C 6 -Cι 4 )aryloxy(C 1 - C 6 )alkyl (C 6 -C 14 )aryl(C 1 -C 6 )alkyloxy, (C 6 -C 14 )aryl(C 1 -C 6 )alkyloxy(C 1 -C 6 )alkyl halogen, trifluoromethyl, trifluoromethoxy, cyano, hydroxy, nitro, ammo, carboxy (C 1 -C 6 )alkoxycarbonyl, carbamoyl, (C 1 -C 6 )alkylthιo, (Cι-C 8 )alkylsulphιnyl (Ci- 2o C 8 )alkylsulphonyl, sulphoammo, (C-ι-C8)alkyisulphonylamιno, sulphamoyl and (C 1 -C 8 )alkylcarbonylamιno, or two of these substituents forming methylenedioxy, 4-carboxyphenyl and substituted 4-carboxyphenyl being excluded from the definition of Ar, Rι, R 2 and R 3 are selected, independently of one another, from 2 - hydrogen, - Ci-C 8 alkyl, (Cι-C 6 )alkoxy(C 1 -C 6 )alkyl group, - cycloalkyl containing from 3 to 8 carbon atoms, (C 3 - C 8 )cycloalkyl(Ci-C 6 )alkyl,(C 3 -C 8 )cycloalkyloxy- (Cι-C 6 )alkyl and (C 3 - C 8 )cycloalkyl(Cι-C 6 )alkoxy(C 1 -C 6 )- alkyl, - C 6 -Cι 4 aryl, C 6 -Cι 4 heteroaryl, (C 6 -Cι 4 )heteroaryl(Cι-C 6 )alkyl, (C 6 - C 14 )aryl(Cι-C 6 )alkyl, (C 6 -C l4 )aryl(C 1 -C 6 )alkyl(C 6 -C 14 )aryl, (C 6 -Cι 4 )aryl(Cι-C 6 )- alkoxy(Cι-C 6 )alkyl and (C 6 -C 14 )aryloxy(Cι-C 6 )alkyl, A, B, C and D are =CH- groups, it being possible for one or two of them also to be a nitrogen atom, R 4 , R 5 and R 6 are selected, independently of one another, from: - hydrogen, - Cι-C 8 alkyl, (Cs-C^cycloalkyKd-C^alkyl, d-C 8 alkoxy, (C 3 - C 8 )cycloalkyloxy(Cι-C 6 )alkyl, (C 3 -C 8 )cycloalkyloxy, (C 3 -C δ )cycloalkyl(d- C 6 )alkoxy, (C 3 -C 8 )cycloalkyl(C 1 -C 6 )alkoxy(Cι-C 6 )alkyl, (Cι-C 6 )alkoxy(C 1 -C 6 )alkyl, C 6 -C 14 aryl, (C 6 -Cι 4 )aryl(C 1 -C 6 )alkyl, (C 6 -C 14 )aryl(C 1 -C 6 )alkyl(C 6 -C 14 )aryl, (C 6 - C 14 )aryloxy, (C 6 -Cι 4 )aryloxy(Cι-C 6 )alkyl, (C 6 -C 14 )aryl(Cι-C 6 )alkoxy, (C 6 - C 1 )aryl(Cι-C 6 )alkyloxy(Cι-C 6 )alkyl, halogen, trifluoro- methyl, trifluoromethoxy, cyano, carboxyl, hydroxyl, nitro, amino, (Cι-C 6 )alkoxycarbonyl, carbamoyl, (Ci- C 6 )alkylthio, (Cι-C 8 )alkylsulphinyl, (C 1 -C 8 )alkylsulphonyl, sulphoamino, (Ci- C 8 )alkylsulphonylamino, sulphamoyl and (Cι-C 8 )alkylcarbonylamιno, it being possible for two of these groups to form methylenedioxy or phenyl ring condensed with the ring to which they are attached, it being possible for the various aryl groups to be themselves substituted by 1 to 3 sub'stituents selected from d-C 8 alkyl, Cι-C 8 alkoxy, halogen, trifluoromethyl, trifluoromethoxy, hydroxyl, nitro and amino, their solvates and their pharmaceutically acceptable salts 2. A compound as claimed in Claim 1 , in which the base component of the ring system is a phenyl ring 3 A compound as claimed in Claim 2, in which at least one of the R 4 R 5 and R 6 groups is Cι-C 8 alkoxy or two of these groups form methylenedioxy 4 A process for the preparation of a compound according to Claim 1 comprising the reaction of an aromatic amine of the formula (II) in which A, B, C, D, Ri, R , R 5 and R 6 are as defined above and R 7 is selected from hydrogen, d-C 6 alkyl and benzyl, with a haloacyl ha de of the formula in which R 2 and R 3 are as defined above, Hal is selected from chlorine and bromine in order to form a compound of the formula (IV) in which A. B, C, D, Ri, R 2 , R 3 , R 4 , R 5 , Re, R? and Hal are as defined above, and the reaction of the compound of the formula (IV) with a compound of the formula (V) in which Ar is as defined above, in the presence of a basic agent, in order to form the compound of the formula (VI) in which Ar, A, B, C, D, R 1 t R 2 , R 3 , R 4 , R 5 , R 8 and R 7 are as defined above, and, in the case where R 7 is alkyl, the hydrolysis of this compound in order to form a compound of formula (I), and, in the case where R 7 is benzyl, the hydrogenolysis of this compound in order to form a compound of formula (I) 5 A pharmaceutical composition comprising an effective amount of a compound as claimed in Claim 1 6 A pharmaceutical composition comprising an effective amount of a compound as claimed in Claim 2 7 A pharmaceutical composition comprising an effective amount of a compound as claimed in Claim 3 8 A method for the treatment of diabetes which comprises administering to a human in need thereof an effective amount of a compound as claimed in Claim 1 9 A method for the treatment of diabetes which comprises administering to a human in need thereof an effective amount of a compound as claimed in Claim 2. 10 A method for the treatment of diabetes which comprises administering to a human in need thereof an effective amount of a compound as claimed in Claim 3.

Inventors: BIERER DONALD D, BOTTON GERARD, DOARE LILIANE, KERGOAT MICHELINE, MESANGEAU DIDIER, MOINET GERARD, PATEREAU GERARD, BIERER, DONALD, D., BOTTON, GERARD, DOARE, LILIANE, KERGOAT, MICHELINE, MESANGEAU, DIDIER, MOINET, GERARD, PATEREAU, GERARD
Applicants: MERCK PATENT GMBH, MOINET GERARD, MOINET, GERARD
Application year: 1998
Main classification: C07D295
IPC codes: C07D295, C07D317